Emergent BioSolutions Inc. has entered into a definitive agreement to acquire Cangene Corp. in an all-cash transaction valued at $222 million. The acquisition is part of Emergent’s growth plan to diversify its revenue mix, adding commercial product sales. The transaction and is expected to close in 1Q14.   Cangene, a specialty therapeutics company focused primarily on biodefense applications, as well as infectious disease, hematology and transplantation, has manufacturing and plasma collection f...